First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
The STRIDE regimen may be beneficial for systemic therapy-naive uHCC patients. High TLR on baseline FDG-PET could be a potentially useful biomarker for response.
Authors
- Shinsuke Uchikawa (ORCID: https://orcid.org/0000-0002-1538-4946)
- Kenji Yamaoka (ORCID: https://orcid.org/0000-0002-8896-3455)
- Eisuke Murakami (ORCID: https://orcid.org/0000-0003-0357-2795)
- Masataka Tsuge (ORCID: https://orcid.org/0000-0001-7591-8287)
- Yuko Nakamura (ORCID: https://orcid.org/0000-0003-3128-4731)
- Tomokazu Kawaoka (ORCID: https://orcid.org/0000-0002-1887-1096)
- Daiki Miki (ORCID: https://orcid.org/0000-0002-6505-9826)
- Yuki Shirane
- Hikaru Nakahara (ORCID: https://orcid.org/0000-0003-2540-707X)
- Atsushi Ono (ORCID: https://orcid.org/0000-0002-2482-945X)
- Hatsue Fujino (ORCID: https://orcid.org/0000-0002-9691-4960)
- Nelson C. Hayes
- Kazuo Awai (ORCID: https://orcid.org/0000-0002-5039-2546)
- Yasutoshi Fujii (ORCID: https://orcid.org/0000-0002-3967-6687)
- Shiro Oka
- Ryoichi Miura
Institutions
- Hiroshima University (JP)
- Hiroshima University Hospital (JP)
Publication Details
- Journal
- Oncology
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1159/000542517
- Citations
- 8
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.96